BrainsWay Announces Data From Feasibility Study Of Deep Transcranial Magnetic Stimulation System For ADHD

BrainsWay Ltd. announced results from a randomized controlled double-blind clinical trial (NCT01196910) assessing the safety and efficacy of the Company’s proprietary H6-coil deep transcranial magnetic stimulation (dTMS) System for the treatment of adults with attention deficit hyperactivity disorder (ADHD). Researchers at Tel Aviv Sourasky Medical Center, Tel Aviv University, Ben Gurion University, and BrainsWay conducted the study, which used functional magnetic resonance imaging to assess the effect of dTMS on clinical, cognitive and neural activity in adults with ADHD. Results showed a statistically significant improvement in self-reported assessments of inattention, together with a significant increase in . . .